Lung cancer screening with low-dose CT can save lives. This European Union (EU) position statement presents the available evidence and the major issues that need to be addressed to ensure the successful implementation of low-dose CT lung cancer screening in Europe. This statement identified specific actions required by the European lung cancer screening community to adopt before the implementation of low-dose CT lung cancer screening. This position statement recommends the following actions: a risk stratification approach should be used for future lung cancer lowdose CT programmes; that individuals who enter screening programmes should be provided with information on the benefits and harms of screening, and smoking cessation should be offered to all current smokers; that management of detected solid nodules should use semi-automatically measured volume and volume-doubling time; that national quality assurance boards should be set up to oversee technical standards; that a lung nodule management pathway should be established and incorporated into clinical practice with a tailored screening approach; that non-calcified baseline lung nodules greater than 300 mm³, and new lung nodules greater than 200 mm³, should be managed in multidisciplinary teams according to this EU position statement recommendations to ensure that patients receive the most appropriate treatment; and planning for implementation of low-dose CT screening should start throughout Europe as soon as possible. European countries need to set a timeline for implementing lung cancer screening.
Introduction
Lung cancer screening with low-dose CT can save lives, and this method will probably be embraced by national health organisations throughout Europe in the future. The results from the US National Lung Cancer Screening Trial (NLST) 1 on reduced lung cancer mortality and from seven pilot trials 2-8 within Europe on other aspects of lowdose CT screening have provided sufficient evidence for Europe to start planning for lung cancer screening while mortality data from the NELSON trial 2 are awaited. This European Union (EU) position statement describes the current status of lung cancer screening and sets out the essential elements needed to ensure the development of effective European screening programmes. The EU position statement expert group comprises individuals from eight European countries who have been actively engaged in the planning and execution of randomised controlled screening trials in Europe, 9 who are involved in the clinical management of patients with lung cancer and lung nodules, and who have developed relevant clinical practice guidelines on smoking cessation, recruitment of high risk participants, patient information literature, as well as CT screening protocols, CT scan radiology reporting, and the clinical management of CT-detected nodules. These experts represent all the specialties and professions involved in delivering successful lung cancer screening programmes in Europe. The emphasis of this EU position statement focuses on the actual implementation of CT lung cancer screening programmes in Europe by radiologists, supported by epidemiologists, pulmonologists, and thoracic surgeons, in the full context of clinical lung cancer diagnosis and treatment. These individuals comprise the core membership of the EU Lung cancer CT Screening Implementation Group (EU-LSIG) and have prepared this EU position statement. We did a comprehensive literature search for papers on lung cancer screening and, through in-depth discussions, developed this EU position statement consensus.
The structure of this document not only reflects the available evidence that addresses the major questions concerning the delivery of a successful screening intervention, but also highlights any issues that still need to be resolved for successful implementation. Contributions to this EU position statement were provided by a team of clinicians and scientists expert in CT as the method of choice for lung cancer screening. The requirement for an EU position statement stems from the need to provide European recommendations on CT screening that will assist the EU Commission and national health agencies in beginning to plan the implementation of lung cancer screening within the next 2 years, and to avoid opportunistic and uncontrolled screening. Moreover, since the publication of the NLST results in 2011, 1 an EU position statement on the value of CT screening for lung cancer is now a crucial necessity.
The focus of this EU position statement is restricted to lung cancer screening with low-dose CT and the early detection of lung nodules before clinical work-up, and does not address the entirety of work-up and treatment choices. Since new randomised controlled trials of lowdose CT screening that are powered to allow conclusions about mortality reduction are highly unlikely, our recommendations are based on the current available data. Data provided by several studies 2, 6, 8 are sufficient to make recommendations concerning the minimisation of false positive results in both screen-detected and non-screen detected nodules. The need for non-contrast-enhanced low-dose interval imaging should not be considered a false-positive test because the individual is not undergoing an invasive clinical work-up and therefore the risk of physical harm is very low. Furthermore, evidence shows that the psychological distress caused is transient and smoking cessation rates increase among those who require interval imaging.
This position statement represents a balance of the available data and therefore reflects which approaches are supported by good evidence, where further evidence is needed to implement effective screening programmes, and where practical implications for lung cancer screening can already be drawn from the available knowledge.
Diagnostic tests for lung cancer detection
CT has progressed to be the best method for lung cancer screening. Previous lung cancer screening trials in the 1980s using chest x-rays with and with out sputum cytology showed no significant survival advantage, 12, 13 which led to inactivity in this field of research for more than two decades. The first publication on lung CT screening in 1999 14 ignited interest in this field again. Other diagnostic methods might have a future potential in lung cancer screening but no trials are yet available to support clinical use. 15 Earlier trials using CT as a screening method provided evidence not only on the effectiveness of lung cancer screening, but also on the natural history of the disease. The debate continued on the ability of CT screening to reduce mortality until the NLST was published, 1 in which 53 454 patients were randomly assigned to receive either low-dose CT or a chest x-ray for screening. This trial had its results reported 1 year earlier than planned because the stop criteria of a 20% reduction in lung cancer mortality rate with low-dose CT had been reached in a periodic planned interim analysis compared with that achieved by chest x-ray. The trial also showed a 6·7% reduction in all-cause mortality with low-dose CT screening (1877 deaths in the lowdose CT group compared with 2000 deaths in the radiography group).
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There is increasing evidence of the effectiveness of CT screening from several pilot trials in Europe and from the NELSON trial publications 2, 16, 17 (table) . However, we need to remain aware of the implications and problems associated with the work-up of suspicious nodules (ie, the invasiveness of biopsies, waiting time until a final decision).
The high false-positive rates both in the initial screening and subsequent screening rounds, as reported in the NLST, need to be reduced to ensure that harmful effects on participants are kept to a minimum. This reduction is best achieved by accurate interval imaging with the latest and most precise methods, particularly semi-automated volumetric analysis rather than manual measurement of maximum diameter, as already implemented by several trials. 2, 7, 8 Furthermore, the definition of false positives also has a major bearing on how we interpret false-positive data. The NELSON, 16 MILD, 3 and UKLS 8 trials defined false positives using baseline data as patients who required a referral to the pulmonologist and who required a further diagnostic investigation (3·5%), but who subsequently did not Since the publication of NLST, the NELSON study 21 has shown that nodules with a volume smaller than 100 mm³ (or <5 mm in diameter) do not confer an increased risk of malignancy at baseline.
Although no other technology is available that could replace CT screening, emerging technologies need to undergo the same scrutiny that has been applied to CT screening to ensure robustness and validity in its use. However, if a new emerging technology is considered, it should be compared with CT screening in a randomised controlled trial, and should show a negative predictive value of almost 100% and a positive predictive value higher than that of CT screening. In the future, some technologies might be applied as an adjunct to CT screening, of which more is discussed later on in this paper.
Outcomes of lung cancer screening trials
The outcomes of various lung cancer screening trials provide insight into how to implement lung cancer screening in differing countries in Europe, as well as the optimal set-up for a population and screening at a single centre. We have learnt much about each stage of the lung cancer CT screening pathway and the management decisions that are required. 22 Ongoing trials 2-8 have provided insight into risk assessment, CT screen nodule manage ment, multidisciplinary team work-up, and surgical interventions, as well as psychological effects on parti cipants and the cost-effectiveness of the screening process.
Several nationally funded randomised studies have already been undertaken in Europe to assess the feasibility of lung cancer screening. These include DANTE, 5 and UKLS. 8, 22 Their results, individually and when pooled, will contribute to the implementation of CT screening in Europe. The only European fully powered randomised controlled trial that will provide mortality and cost-effectiveness data is the NELSON trial, but we do have sufficient data to start planning before the full results are available. The results from NLST alone have been sufficient for low-dose CT screening to start in the USA and Canada.
The incorporation of the coronary artery calcification score and emphysema assessment on low-dose CT imaging might enhance the cost-effectiveness and attractiveness of low-dose CT lung cancer screening. 24 Chronic obstructive pulmonary disease (COPD) and emphysema are the strongest lung cancer risk predictors and, together with cardiovascular disease, all three imaging biomarkers have substantial effects on morbidity but also have independent effects on overall mortality. 25, 26 Lung cancer risk prediction modelling
The concept of clearly defining a target population for lung cancer screening is gaining importance. 19, 27 Selection on the basis of age alone, as in most other cancer screening disease settings (eg, breast and colon), is insufficient in lung cancer because of other powerful risk factors, the most important of which is exposure to tobacco smoke. Other major risk factors, which are also taken into account, include a history of respiratory diseases (COPD, emphy sema, bronchitis, pneumonia, and tuberculosis), pre vious malignancy, family history of lung cancer (first-degree relative diagnosed at age 60 years or younger), and exposure to asbestos. Several multivariable risk prediction models have been published, 28 [30] [31] [32] The LLP v2 is the only risk model that has been used so far to select patients for a lung cancer screening randomised controlled trial. 8 In this trial, a higher percentage of participants were diagnosed with lung cancer at baseline than those in the NLST and NELSON trials. The LLP v2 model cutoff of 5% over 5 years is being validated in the Liverpool Healthy Lung Project. 27, 33, 34 The original LLP model has compared favourably with the Spitz and Bach models. 35 The LLP model was validated in the UK with the use of data from a population-based prospective cohort study, 33 with an area under the curve (AUC) of 0·82 (95% CI 0·80-0·85). 33 The Bach, Spitz, LLP, and modified PLCO (PLCO m2012 ) risk models were externally validated in the German EPIC cohort study 36 of 20 700 ever-smokers. The PLCO m2012 model showed the best performance in external validation (C index 0·81, 95% CI 0·76-0·86) and the highest sensitivity, specificity, and positive predictive value compared with the other three models. However, the superiority of the PLCO m2012 model over the Bach and LLP models was considered modest by the authors. 36 Five different risk models have been compared with one another by use of the PLCO and NLST trial datasets. 37 Although several sophisticated models have used a range of risk variables (ie, family history, previous malignancy, previous respiratory disease, exposure to asbestos), the Bach model had a good sensitivity and specificity, 28 even though it only used age and smoking history for cal culating risk score, emphasising the importance of these two risk factors. The PLCO m2012 model also provided good results, Policy Review but this model was developed using the PLCO dataset, so there might be issues of overfitting. However, all the models compared were superior to the NLST selection criteria and the USPSTF recommendations. The PLCO m2012 risk model was also used to calculate the predicted risk of lung cancer from baseline data from 95 882 ever-smokers aged 45 years or more in the Australian 45 and Up Study (2006-09). 38 The results showed good discrimination (AUC 0·80, 95% CI 0·78-0·81) and excellent calibration. Thus, the use of risk prediction models is essential in the selection of patients for lung cancer screening. Costeffectiveness was also increased in the high-risk groups 38 meaning that risk prediction should also reduce costs per life saved. There is no information on related costeffectiveness. 37 We recognise that the aforementioned risk prediction models were based on European populations and that lung cancer risk predictions might be affected by regional differences. This EU position statement does not recommend any specific risk prediction model, but either the PLCO m2012 or the LLP v2 would suffice if screening were to be implemented immediately.
We need to be aware of the different European health care systems and the issues concerning the use of a risk stratification approach (such as in Germany, in which all individuals have a legal right of access to the available diagnostic and therapeutic techniques). However, it should be argued that screening low-risk patients would be unethical because of harm-to-benefit considerations.
The risk profile of those targeted for screening is a valuable and cost-effective tool to identify those with preclinical disease who are eligible for screening. 8, 30 The integration of the risk profile with one or more biomarkers or susceptibility genes could improve the selection of high-risk patients for screening, the management of disease, or both. 39, 40 Predictive biomarkers, such as microRNA markers, are potentially effec tive tools for the identification of susceptible patients and future lung cancer cases, [41] [42] [43] while a bronchial airway gene-expression classifier could improve the diagnostic per formance of bronchoscopy. 42 Breath tests for lung cancer should be considered a strong possibility for screening and are being tested in clinical trials. 43, 44 The identification of new biomarkers for screening will be a reason to implement cooperative research. The availability of large, high-quality biobanks embedded in screening trials together with radiomic analysis is a future opportunity that should be explored further in a lung cancer screening context.
Harms and benefits associated with lung cancer screening
The harms associated with lung cancer screening, such as overdiagnosis, surgery for benign lesions, psychological harm, and radiation exposure, need to be acceptable before the implementation of screening. Minimising harm is essential to maximise the clinical effectiveness of the intervention.
Physical harms can be reduced by ensuring that only patients with a sufficiently high risk of developing lung cancer are screened, by reducing screening radiation dose to a minimum, and by the effective management of atypical findings, including nodules, suspected lung cancers, and incidental findings. These measures require a high degree of clinical expertise to be available so that all aspects of CT screening and management are completed to the highest standards. Thus, lung cancer screening should only be undertaken according to protocol, and at screening units and centres that are able to guarantee rigorous quality control.
According to the guidelines of the European Society for Medical Oncology (ESMO) 45 and the European Society of Thoracic Surgeons, 46 low-dose CT screening can be done outside a clinical trial setting if it is offered within a screening programme with quality control and in a centre with CT screening experience, extensive thoracic oncology activity, multidisciplinary management of suspicious findings, and a well-developed programme of minimally invasive thoracic surgery. Psychological harms Policy Review can be reduced by providing information about CT screening in a language that is understood by those who are screened, including details about atypical findings, with accurate information about the probability of cancer, especially where findings are likely to be benign. The potential physical harms of screening should be provided to attendees in a clear manner, including harm from radiation exposure 47 and the harms from a biopsy or resection of a benign lesion. However, the radiation risk is likely to be overestimated and will decrease in the future with the arrival of the latest CT platforms, with ultra low-dose CT technology. All European trials will provide data that will allow a direct quantification of overdiagnosis. The proportion of benign resections in clinical trials varies from 10% to at least 25% of all operations.
3, 8 Our consensus indicates that a prevalence of 10% or lower for lung cancer should be reached, but an optimal percentage has not been established yet. It should be noted that the dynamic between patient and physician is altered in a lung cancer screening setting when compared with settings where symptomatic individuals present them selves to health-care institutions.
Effective implementation of lung cancer screening programmes also includes recognition of the benefits of maximising smoking cessation within CT screening programmes. Smokers should be informed of the dangers of continuing to smoke for their own general health and should be offered suitable support to help quit. [48] [49] [50] 
CT methodologies for early lung cancer detection
In the NLST trial, a CT screen was regarded as positive if it showed any non-calcified nodule of at least 4 mm in diameter. The American College of Radiology set up a Lung Cancer Screening Committee subgroup to develop Lung-RADS, 51 ,52 a quality assurance tool with which to standardise the reporting of lung cancer CT screening and to inform management recommendations. The rationale behind this initiative was that it would assist in the interpretation of nodule findings.
A comparison of Lung-RADS performance with NLST data 53 showed that Lung-RADS substantially reduced the false-positive result rate, but also reduced screening sensitivity. Mehta and colleagues 54 have suggested that the Lung-RADS system needs to be revised, and they faulted the system on the basis that it has never been studied in a prospective manner. Additionally, Li and colleagues 55 have analysed the effect of the so-called rounding method used in Lung-RADS on the frequency of positive results and on the growth assessment of pulmonary nodules. The authors con cluded that rounding up the mean nodule diameter in Lung-RADS increased the frequency of positive results, leading to a detrimental effect on the efficiency of lung cancer screening. Furthermore, Lung-RADS does not provide guidance on risk prediction models. The Brock score provides a more accurate estimate of a nodule's risk of malignancy than baseline Lung-RADS criteria. 56, 57 An alternative method is to determine nodule volume using a software for semi-automated segmentation, which enables an accurate estimation of nodule size after 
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three-dimensional reconstruction (figure 1). Volumetric analysis of CT-detected nodules was initially recommended by Henschke and colleagues 14 in 1999, and has been further developed and validated in the NELSON and the UKLS trials. A comparative analysis 58 
59
The recommendation for the future management of solid nodules detected with CT screening is that semiautomatically derived volume and volume-doubling time should be used in preference to diameter measurements, which should only be used where volumetry is not technically possible.
Prerequisites for lung cancer population screening
The accreditation awarded to institutions and radiologists participating in lung cancer CT screenings should include training in the implementation of quality assurance processes.
The
National quality assurance boards should be set up to monitor the adherence to minimum technical standards and to standardise diagnostic criteria for screen-detected lung nodules, similar to the UK and European breast Policy Review screening programmes. [60] [61] [62] Such national quality assurance boards should be entitled to advise or intervene whenever basic requirements are not met. The lung cancer community should consider following the example of the Dutch breast cancer screening service by organising socalled central reading centres of all CT screening programmes across the country. 62 This ap proach is favoured over a local reading of CT scans as the latter could have a major effect on routine radiology service delivery. This approach would also enable ongoing national quality assurance control and the introduction of the forefront automated pulmonary nodule reading software.
Institutions participating in screening programmes require multidisciplinary teams to represent all relevant specialities (including a pulmonologist, thoracic surgeon, radiologist, lung cancer nurse, and so on) in which suspicious screening results can be discussed. These institutions should regularly demonstrate to a quality assurance board that they continue to meet basic standards similar to those proposed by the Radiological Society of North America. 63 
Lung nodule management at baseline CT screening
The management of prevalent lung nodules should mostly depend on size criteria. Volumetry is essential, but diameter cutoffs need to be provided for cases in which segmentation is not possible. Minimum standards for CT acquisition parameters in lung cancer screening need to be met to ensure the standardisation of volumetric analysis (ie, protocol regarding slice thickness, reconstruction interval, and image reconstruction algorithm [kernel]), and to clearly define the low radiation dose.
The management of screen-detected lung nodules should be based on the evidence from screening trials that have used volumetry, such as the NELSON trial. In the original NELSON nodule management protocol, 2 volume cutoffs for negative and positive screen results were less than 50 mm³ for negative and more than 500 mm³ for positive results. Nodules with a volume of 50-500 mm³ were classified as indeterminate. These cutoffs could be optimised on the basis of lung cancer probability results of the first two screening rounds from the NELSON trial. 21 For example, for solid nodules with a volume of less than 100 mm³, the patient should return for an annual screen; for nodules with a volume of 100-300 mm³, the patient should return for a repeat screen in 3 months; for volumes greater than 300 mm³, the patient should be referred to a multi disciplinary team. 21 Figure 3 64 shows the recom mended nodule management protocol for screen-detected solid nodules at baseline, figure 4 64 for screen-detected incidental Policy Review nodules at follow-up, figure 5 for clinically detected solid nodules according to British Thoracic Society (BTS) guidelines, and figure 6 for sub-solid nodules for both screen-detected and clinically detected nodules. Detailed risk profiles for the probability of lung cancer over 2 years are shown in figure 7 . 21 Data to inform this figure have been provided by the NELSON group for both nodule volume and volume-doubling time (<400 days and 400-600 days-an increased risk, described in figure 3 ; >600 days, no substantially increased risk), which provides guidance to the future follow-up interval for specific participants. In 2017, a study 65 provided in-vivo evidence for the growth patterns of screen-detected lung cancers, showing an exponential growth pattern that can be described by the volume-doubling time. Acknowledging that software packages give different estimates of solid nodule volume, commonly around 20% of difference (corresponding to a non-measurable 7% error in nodule diameter; absolute 0·4 mm error), 66 there might be merit in decreasing the nodule volume threshold for a repeat screen at 3 months to 80 mm³ if the software is not phantom validated (a calibration process for quality assurance of different CT scanners; figure 5).
For sub-solid nodules, surveillance should be favoured over intervention to avoid overdiagnosis. For all pure ground glass nodules and most partial solid nodules, a return to annual screening is recommended (figure 6). 67 Knowledge and data from ongoing lung cancer screening projects will also be important for the future optimisation and refinement of nodule management protocols.
Morphology assessment should also play a part in the management of solid nodules, such as clustered, ill-defined nodules, which are more consistent with inflammatory aetiologies, or smooth peri-fissural nodules or intrapulmonary lymph nodes, which require management not based purely on size criteria. 68 There are several alternative work-up methods for screendetected suspicious nodules with volumes larger than 300 mm³ at baseline, such as core needle biopsy, PET or CT scans, and primary resection.
The management of a patient should be done according to their risk of malignancy. Low-risk nodules, such as those with a risk of malignancy lower than 10%, can be followed up with interval imaging, but high-risk nodules need further work-up if it is agreeable to the patient after an informed discussion. As the risk of Policy Review malignancy increases, management options broadly include further surveillance, biopsy, or treatment. ESMO guidelines published in 2017 45 indicate that the cornerstone of treatment of potentially resectable lung cancer is the surgical removal of the tumour. For patients who are not willing to accept the risks of surgery, or for whom surgery is a high-risk option, non-surgical therapy should be offered. This option could be either stereotactic ablative radiotherapy, hypofraction ated high-dose radiotherapy or image-guided ablative therapy. 45 
Incident screening rounds
Although incident screening rounds will constitute much of the work in the early detection of lung cancer, until recently research did not focus on incident nodules and their definition, which has varied widely between lowdose CT lung cancer screening trials. 8, 64, 69, 70 Incident nodules detected in high-risk individuals after baseline screening had either been missed in a previous scan or had developed de novo in the time interval since the previous scan. In the event of a missed nodule, calculation of the volume-doubling time is advised for further risk stratification. However, patients with newly developed nodules are a specific group that is distinct from patients that have had nodules detected at baseline. With an annual incidence of between 3% and 13% of participants, these newly developed nodules are regularly encountered in low-dose CT lung cancer screening. [71] [72] [73] [74] Unlike baseline nodules, which could have been present for years before detection, new incident nodules are potentially fastgrowing. 17, [75] [76] [77] This potential is reflected in a high cancer risk of 2-8% for participants with a new incident nodule. 17, 71, 72, 74 Because these nodules have less time to grow before detection than those nodules detected previously, baseline cutoff values are not applicable. 17 This formerly theoretical concept, which led to an adjustment of cutoff values for new incident nodules in several trials, 53, 72, 77 has been supported for new solid incident nodules by the results of the NELSON trial. 17 Because a large proportion (37-57%) of new incident nodules are very small (<50 mm³ in volume), 17, 71, 74 volume measurements should be preferred, since diameter measurements are much less precise and reproducible. Data from the NELSON trial suggest that new solid incident nodules should be categorised in three groups: nodules smaller than 27 mm³ in volume (<1% lung cancer probability) represent a low-risk group, and these patients could return to the annual screen schedule (based on an annual screening programme); patients with new solid incident nodules of 27-207 mm³ in volume (3% lung cancer probability) form an intermediate-risk group requiring a repeat low-dose CT in 3 months; and patients with new non-calcified solid incident nodules equal or greater than 208 mm³ in volume (17% lung cancer probability) form a high-risk group requiring referral to a multidisciplinary team. 17 We suggest simplifying these categories to volumes smaller than 30 mm³, 30-200 mm³, and equal or greater than 200 mm³ (figure 4). The existing data indicate that the majority (68-86%) of lung cancers found in new incident nodules during lung cancer screening are detected at stage I. 17, 72 Therefore, volume-doubling time assessment at follow-up scans appears appropriate, as outlined in the BTS guidelines. 64 However, the available evidence regarding new incident nodules is insufficient, and a more standardised approach to reporting, such as strictly separating baseline and incident nodules, could simplify the recommended routine clinical management of patients with newly detected incident nodules. If a CT scan is done less than 2 years before screening is available, recommendations for new inci dence nodules detected during screening could be extrapolated to routine clinical practice in a high-risk patient population, similar to that done in the NELSON trial. This recommendation has now been adopted by the BTS guidelines on nodule management, 78 and by the BTS Quality Standard on lung nodule management. In a low-risk population, the management of patients should follow BTS guidelines.
Clinical work-up of CT-detected lung nodules in clinical practice
Incidentally detected lung nodules are an increasingly common clinical problem arising from the increased use of cross-sectional imaging in clinical practice. The BTS has undertaken the in-depth task of developing guide lines on the management of pulmonary nodules in a clinical context, separate from the context of population screening. 64 This work has been based on an extensive Policy Review review of the literature, which included publications from several lung cancer CT screening trials, and an in-depth analysis of the data. The guideline development group used methods compliant with the AGREE Collaboration criteria and standards set by NHS Evidence. The evidence review was comprehensive, done in November, 2012, and updated in June, 2014. The guidelines provide four management algorithms and two malignancy prediction tools: 64 the Brock risk prediction tool to calculate malignancy in solid pul monary nodules equal or larger than 5 mm in volume, which are unchanged at 3 months, 56 and the Herder prediction tool to be used after PET/CT. 79 Furthermore, volumetry has been recommended by BTS as the preferred measurement for CT-detected nodules. The guidelines also provide recommendations for the management of nodules with extended volume-doubling times.
The BTS guidelines provide recommendations on the use of further imaging and PET/CT information that can be incorporated into pulmonary risk models (Herder model) , and advice on biopsy and the threshold for treatment without histological confirmation. BTS also provides advice on the information that should be given to patients about the management of pulmonary nodules in a non-screening context. This EU position statement recommends keeping a database of all nodules that can facilitate a future refinement of nodule management in line with new evidence.
Optimal timing of lung cancer screening intervals
The USPSTF on CT screening has recommended annual screening from age 55 years to 80 years. 80 In a NELSON publication, 81 a 2·5-year screening interval resulted in a significant increase in in terval cancers in the fourth screening round, providing evidence against using this interval in a future screening programme. There were also significantly more interval cancers in a 2·5-year timeframe, and a trend towards more cancers detected at a later stage. A detailed analysis of the cost-effectiveness of various screening scenarios showed that almost all approaches increase cost-effectiveness when screens are annual. 82 However, half of the participants included in the NELSON trial had no pulmonary nodules detected, and the 2-year probability of participants developing lung cancer was 0•4%, indicating that a screening interval of up to 2 years could be considered for similar individuals in future screening programmes, in a risk-stratified approach. The only trial to test annual and biennial screening was the MILD trial, 83 in which no difference was found in terms of mortality when comparing these two screening intervals.
Screening intervals have been modelled by both the UKLS trial 84 and the International Early Lung Cancer Action Program. 85 Duffy and colleagues 84 acknowledged the risk of increasing the number of screening intervals but also acknowledged that it could potentially provide a more cost-effective approach. Yankelevitz and colleagues 85 argued that we should move beyond hypothesis testing and onto quantification. We need to learn how the length of the interval between screens affects the diagnostic distribution before we consider changing annual screening intervals.
So far, we only have trial evidence for annual screening. Studies have shown that previous negative screening results might provide directions for further risk stratification. 86, 87 Future decisions regarding interval timing should be based on risk, psychosocial effects, 88 cost-effectiveness, and the feasibility of implementation, 89 but these areas require further investigation. However, with new ultra-low-dose CT techniques, the radiation
Panel 1: European Union (EU) position statement recommendations
We recommend the following actions to begin implementation of lung cancer screening in Europe: 1 Low-dose CT is the only evidence-based method for the early detection of lung cancer shown to provide a mortality reduction. On the basis of this evidence from randomised controled trials, the EU position statement recommends that we start to plan for the implementation of lung cancer screening in Europe while cognisant of future publications that include the awaited NELSON trial data on mortality and cost-effectiveness and data from the six smaller European studies for developing implementation strategies in each of their own countries. 2 Future lung cancer low-dose CT programmes should use a validated risk stratification approach so that only individuals deemed to be at high enough risk are screened. In the near future, incorporation of potential biomarkers and susceptibility genes into lung cancer risk models should be considered to improve the accuracy of risk stratification models. 3 All future screenees entering into early detection programmes for lung cancer should be provided with carefully constructed participant information on the potential benefits and harms of screening to enable them to make an informed decision as to whether they wish to participate or not. Smoking cessation advice should be offered to all active smokers. 4 Future management of screen-detected solid nodules should utilise semi-automatically derived volume measurements and volume-doubling time, and should be quality assured. 5 National quality assurance boards should be set up by professional bodies to ensure adherence to all minimum technical standards, including semi-automated volumetry, and to standardise diagnostic criteria for screen-detected lung nodules, including radiation exposure limits. 6 Management of prevalent lung nodules in CT screening programmes, lung nodules at incident screening (newly detected), and CT-detected lung nodules in clinical practice should be managed with different protocols because of different pretest lung cancer probabilities. 7 Although only evidence for annual low-dose CT lung cancer screening is available, recent research suggests the possibility of using a more personalised approach to lung cancer screening with a risk-based approach on the results of baseline and first screening rounds. 8 Management of lung nodules by lung cancer multidisciplinary teams should be done according to the EU position statement recommendations with the aim of minimising harm and ensuring patients receive the most appropriate treatment. 9 The EU position statement expert group recommends that the planning for low-dose CT screening should be started throughout Europe because low-dose CT lung cancer screening has the potential to save lives.
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dose for repeated CT screenings over a 30-year period might not be a major issue for participants. New developments, such as deep machine learning, will assist in the automation of pulmonary nodule management in lung cancer screening. 90 In the future, we think that, with implementation of ultra-low-dose CT screening, there will be no obstacles in tailoring the frequency of screening of high-risk individuals over a 25-year period. We should be considering precision medicine in the field of lung cancer screening, and whether an individual who has had a negative baseline and a negative 1-year scan should be moved into biennial screening until their risk profile changes. As lung cancer screening is still in an embryonic stage of implementation in Europe, we have an opportunity to plan the development of an optimal lung cancer low-dose CT screening strategy.
91

Conclusion
This EU position statement describes the current status of lung cancer screening in Europe. Through consensus discussions with experts from the eight European countries undertaking randomised controlled trials of lung cancer CT screening, we have developed nine recommendations to guide the implementation of lung cancer screening in Europe (panel 1). Some specific areas still require further development and consideration, such as the integratation of smoking cessation into lung cancer screening programmes and the selection of the appropriate target screening population. However, evidence clearly shows that Europe must start planning for implementation within the next 18 months, as outlined here (panel 2). During this planning period, each country will need to focus on deciding the best risk prediction method for the identification and recruitment of high-risk populations and on setting up the required infrastructure for quality-controlled CT scans that use volumetric analysis. This EU position statement has provided detailed recommendations on the management of lung nodules by lung cancer multidisciplinary teams, with the aim of minimising harm and ensuring that patients receive the optimal diagnosis and therapy.
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